We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collagen Biomarkers Clarify Prognosis of Diabetic Renal Complications

By LabMedica International staff writers
Posted on 24 Jul 2019
Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin. More...
Insulin is a hormone needed to allow sugar (glucose) to enter cells to produce energy.

One cause of kidney failure is diabetes mellitus, a condition characterized by high blood glucose levels. Over time, the high levels of sugar in the blood damage the millions of filtering units within each kidney and this eventually leads to kidney failure. Around 20% to 30% of people with diabetes develop kidney disease (diabetic nephropathy), although not all of these will progress to kidney failure.

A team of scientists working with the Steno Diabetes Center Copenhagen (Gentofte, Denmark) measured by enzyme-linked immunosorbent assay (ELISA) serum and urinary levels of two biomarkers, serum PRO-C6, a biomarker of collagen type VI formation, and urinary C3M, a biomarker of collagen type III degradation. C3M was measured in three urine samples taken between 2009 and 2011 from 663 adults with type 1 diabetes (mean age, 54.6 years; 44% women). The participants were then followed until the end of 2016. During follow-up, the investigators identified instances of cardiovascular (CV) and renal death, nonfatal acute myocardial infarction, nonfatal stroke, coronary interventions, end-stage renal disease, chronic dialysis and kidney transplant as well as measures of estimated glomerular filtration rate (eGFR) from medical records.

The team reported that high levels of serum PRO-C6 were independently associated with a higher risk of all-cause mortality (HR 2.26). Based on median cutoffs, serum PRO-C6 measures of 7.5 ng/mL or more were associated with reduced eGFR, increased urinary albumin excretion rate and greater diabetes duration. The team noted that noted this increased mortality risk was present but only for participants with a urinary albumin excretion rate of less than 30 mg per 24 hours. In addition, an association between serum PRO-C6 and a worsening of 30% or more in eGFR was observed only in participants who had a baseline eGFR of more than 30 mL/min/1.73 m2. The scientists noted that end-stage renal disease (ESRD) was 8.45 times more likely to develop in participants with serum PRO-C6 measures of at least 7.5 ng/mL (HR = 8.45).

Sascha Pilemann-Lyberg, MD, PhD, the first author of the study, and her colleagues said, “Collagens are an essential part of the fibrotic structure, acting as a scaffold for a range of [extracellular matrix] molecule interactions and cell adhesion. “Because increased collagen formation and reduced degradation are closely linked with the development of fibrosis, assessment of collagen formation and degradation may identify patients with active fibrosis at higher risk of CV [events] and heart failure, mortality, and rapid deterioration of kidney function.” The study was published in the July 2019 edition of the journal Diabetes Care.

Related Links:
Steno Diabetes Center Copenhagen


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Immunofluorescence image of reactive astrocytes (red) in the area surrounding sEcad-high cancer cells (blue, center) (Photo courtesy of Debeb Laboratory)

Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis

Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.